Evidence map›Paper›PMID 42286211›Full record

ArticleCommunications biology2026

Multi-drug tolerance in Leishmania persister-like cells.

Allison Aroni-Soto, Pieter Monsieurs, Odin Goovaerts, Kaoutar Choukri, Basudha Khanal, Wim Adriaensen, Jean-Claude Dujardin, Michael P Barrett, Malgorzata A Domagalska

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Allison Aroni-SotoInstitute of Tropical Medicine, Experimental Parasitology Unit, Antwerp, Belgium.ORCID 0000-0001-6741-3481
Pieter MonsieursInstitute of Tropical Medicine, Experimental Parasitology Unit, Antwerp, Belgium.ORCID 0000-0003-2214-6652
Odin GoovaertsInstitute of Tropical Medicine, Clinical Immunology Unit, Antwerp, Belgium.
Kaoutar ChoukriInstitute of Tropical Medicine, Experimental Parasitology Unit, Antwerp, Belgium.
Basudha KhanalDepartment of Microbiology, BP Koirala Institute of Health Sciences, Dharan, Nepal.
Wim AdriaensenInstitute of Tropical Medicine, Clinical Immunology Unit, Antwerp, Belgium.ORCID 0000-0002-9698-7449
Jean-Claude DujardinDepartment of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-9217-5240
Michael P BarrettSchool of Infection & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0001-9447-3519
Malgorzata A DomagalskaInstitute of Tropical Medicine, Experimental Parasitology Unit, Antwerp, Belgium. mdomagalska@itg.be.ORCID 0000-0003-0839-0325

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is caused by parasitic protozoa of the genus Leishmania and is found widely across the tropics and sub-tropics, afflicting hundreds of thousands of people. The disease is notoriously difficult to treat. Here, we present evidence of the existence of persister-like cells in cultured Leishmania populations, induced upon exposure to normally lethal doses of antimony, a still used anti-leishmanial. Persisters are a small fraction of non-proliferative cells with reduced metabolism that are adapted to withstand a variety of environmental assaults, including lethal doses of antimicrobials. We show that Leishmania persister-like cells survive lethal doses of antimonials by adopting a quiescence phenotype characterised by reduced proliferation, constrained metabolism, diminished mitochondrial membrane potential and downregulated transcription of core metabolic pathways. What is more, these cells demonstrate cross-tolerance to other anti-leishmanial drugs. Wild-type persister-like cells reverted to similar levels of drug susceptibility once the antimony-induced pressure was removed. Surprisingly, cells from strains with genetic changes causing resistance to antimony acquired a level of hyper-resistance after transient passage through the quiescent state, without further genetic change. Our results demonstrate the extreme versatility of this eukaryotic pathogen in adaptation to drug pressure and highlight the need for the development of new anti-leishmanials targeting non-proliferative forms.

Indexed as

AntimonyAntiprotozoal AgentsDrug Resistance, MultipleDrug ToleranceLeishmaniaAnimalsHumansMembrane Potential, MitochondrialAntimonyAntiprotozoal Agents

Identifiers

PMID42286211
PMCPMC13616925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.